vTv Therapeutics (NASDAQ: VTVT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.080 | -0.100 | -0.0200 | ||||
REV | 2.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of vTv Therapeutics (NASDAQ: VTVT) through any online brokerage.
Other companies in vTv Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Lumos Pharma (NASDAQ:LUMO), Aligos Therapeutics (NASDAQ:ALGS), Infinity Pharmaceuticals (NASDAQ:INFI) and Sensei Biotherapeutics (NASDAQ:SNSE).
The latest price target for vTv Therapeutics (NASDAQ: VTVT) was reported by Cantor Fitzgerald on Friday, February 18, 2022. The analyst firm set a price target for 5.00 expecting VTVT to rise to within 12 months (a possible 532.91% upside). 1 analyst firms have reported ratings in the last year.
The stock price for vTv Therapeutics (NASDAQ: VTVT) is $0.79 last updated June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for vTv Therapeutics.
vTv Therapeutics’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for vTv Therapeutics.
vTv Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.